Selected References
  • Fiore F, Gadaleta CD, Granetto C, et al. Phase II trial of Nemorubicin hydrocloride (Nemorubicin) in combination with cisplatin (cDDP) in patients (pts) with hepatocellular carcinoma (HCC): First step results, American Society of Clinical Oncology Annual Meeting 2009,May 31(Abs 4593)
  • Sun Y,Yang J, Luo P, et al. Efficacy of Nemorubicin (MMDX) administered with iodinated oil via hepatic artery (IHA) to patients with unresectable primary hepatocellular carcinoma (HCC): phase II trial. EJC 2004; vol.2 (8), Abstract 470.
  • Geroni C, Quintieri L, Valota O, et al. Preclinical activity against liver metastases of nemorubicin, a DNA-intercalating cytotoxic agent for the treatment of hepatocellular carcinoma. Eur J Cancer, 38(7): 45, S19, 2002.
  • Quintieri L, Rosato A, Napoli E, et al. In vivo antitumor activity and host toxicity of methoxymorpholinyl doxorubicin: role of cytochrome P450 3A., Cancer Res. 2000 Jun 15;60(12):3232-8
  • Sessa C,  Zucchetti M, Ghielmini M, et al.   Phase I clinical and pharmacological study of oral methoxymorpholinyl doxorubicin (PNU 152243)., Cancer Chemother Pharmacol. 1999;44(5):403-10        
  • Bakker M, Droz JP, Hanauske AR, et al. Broad phase II and pharmacokinetic study of methoxy-morpholino doxorubicin (FCE 23762-MMRDX) in non-small-cell lung cancer, renal cancer and other solid tumour patients., Br J Cancer. 1998;77(1):139-46     
  • Danesi R, Agen C, Grandi M, et al.  3'-Deamino-3'-(2-methoxy-4-morpholinyl)-doxorubicin  (FCE  23762):  a new  anthracycline  derivative with enhanced cytotoxicity and reduced cardiotoxicity. Eur J Cancer, 29A:1560-5, 1993.
  • Ripamonti M, Pezzoni G, Pesenti E, at al. In vivo antitumour activity of FCE23762, a methoxy morpholinyl derivative of doxorubicin active on doxorubicin-resistant tumour cells.  Br J Cancer, 65:703-7, 1992.
To give you a better browsing experience, NMS Group and Group Companies use own and third part cookies.
Browsing this web site, you allow to use them, according to our  
Cookie Policy.